Interview with Martin Nelzow, CEO, Boehringer Ingelheim Brazil
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
Address: Rochaverá Corporate Towers. Av. Nações Unidas, 14.171 – Torre Marble – 18º andar – São Paulo – SP. CEP: 04794-000
Tel: (11) 4949-4700
Web: http://www.boehringer-ingelheim.com.br/principal.asp
The Boehringer Ingelheim group is one of the top 20 pharmaceutical companies in the world. Headquartered in Ingelheim, Germany, operates globally with 138 affiliates in 47 countries and 41,300 employees. Since its founding in 1885, this family business is committed to researching, developing and marketing novel products of high therapeutic value for human and veterinary medicine.
Present in Brazil since 1956, headquartered in Sao Paulo and factory in Itapecerica da Serra (SP), the company employs approximately 1,000 employees and sells products with brands like Anador ®, Bisolvon ®, Buscopan ®, Dulcolax ®, and Mucosolvan ® ® Pharmaton , and several prescription products, with an outstanding performance in the areas respiratory, cardiovascular, Parkinson’s and others.
Located in Itapecerica da Serra, São Paulo, the Brazilian plant has excellence in the manufacture of medicines and is one of the largest and most modern of the group in the world, accounting for the 3rd largest production volume, representing 10% of the company’s global . Through its Industrial Business Area, the plant of Boehringer Ingelheim in Brazil also produces products for other laboratories.
Since 1998, Boehringer Ingelheim has been designated by the Great Place to Work Institute as one of the 100 best companies to work in Brazil. In total, there have been nine nominations, eight of them consecutive. Since 2004 the company has also been designated by the Great Place to Work as one of the best companies to work in Latin America.
Anador ®, Bisolvon ®, Buscopan ®, Dulcolax ®, and Mucosolvan ® ® Pharmaton
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
Renata Mihich, a 25-year DHL veteran, recently took on a new role as Head of LatAm for Italian healthcare logistics specialist BOMI GROUP. At a moment of career transformation, BOMI…
While regulatory agencies in several Latin American countries have made significant efforts to improve processes and accelerate approval times, a number of access hurdles still remain across the region. Here,…
Rolf Hoenger describes how Roche is driving access and awareness for innovative medicines in Latin America and weighs in on a number of important topics, from regulatory harmonisation in the…
After a successful international career, Andre Vivan da Silva recently returned to his native Brazil to become GSK’s country manager. He explains the importance of vaccination, in Brazil, and HIV…
Although Brazil is one of the world’s top pharma markets, with the highest market value in Latin America, and has made major strides towards universal healthcare, the country continues to…
Novo Nordisk’s Latin America lead Allan Finkel outlines the “alarming” burden of diabetes and obesity in his region, the progress that has been made via national campaigns against diabetes, and…
GSK’s head of Emerging Markets, Luis Arosemena, comments on the strategic importance of this wide-ranging country grouping for the company, the structure of his organisation in Latin America, the importance…
The latest from Brazilian Pharma, including the approval of home grown cannabis for medical use, Cellera Farma’s partnership with Ferring, a considerable increase in demand for oncology drugs, and a…
The latest from the healthcare industry in Latin America, including an alarming OECD report about the decline of well-being in the region due to Covid-19, Bayer’s USD 350 million investment…
The latest news from Brazil, including Pfizer’s plans to vaccinate the entire Brazilian city of Toledo, what the US can learn from Brazil’s successful vaccine campaign, and a new deal…
The latest news from Brazilian pharma, including an investigation into the country’s deal with Indian lab Bharat Biotech to purchase COVID-19 vaccines; the IP and regulatory challenges around personalised medicine…
Founded in 1950, EMS is one of the top two domestic pharma companies in Brazil. As a key player in the largest and most populous nation in Latin America, the…
See our Cookie Privacy Policy Here
